A review of the pharmacokinetic profile of transmucosal fentanyl formulations

Current Medical Research and Opinion

Volumn 28, Issue 11, 2012, Pages 1781-1790

  Moore, Nicholas ^a   Darwish, Mona ^b   Amores, Xavier ^b   Schneid, Hélène ^b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b Cephalon Europe   (France)

Author keywords

Administration, mucosal; Analgesia; Analgesics, opioid; Breakthrough pain; Fentanyl; Pharmacokinetics

Indexed keywords

FENTANYL; FENTANYL CITRATE; ORAVESCENT; UNCLASSIFIED DRUG;

ANALGESIA; BREAKTHROUGH PAIN; DRUG BLOOD LEVEL; DRUG FORMULATION; HUMAN; MEDLINE; PHARMACOKINETICS; REVIEW;

ADMINISTRATION, ORAL; ANALGESICS, OPIOID; FENTANYL; HUMANS; MOUTH MUCOSA; PAIN;

EID: 84868684845     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.735227     Document Type: Review

References (54)

1. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41:273-81
2. Caraceni A, Martini C, Zecca E, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 2004;18:177-83
3. Portenoy RK, Bennett DS, Rauck R, et al. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J Pain 2006;7:583-91
4. Svendsen KB, Andersen S, Arnason S, et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 2005;9:195-206
5. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain 1999;82:263-74
6. Davies A, Zeppetella G, Andersen S, et al. Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain 2011;15:756-63
7. Portenoy RK. Treatment of cancer pain. Lancet 2011;377:2236-47
8. Zeppetella G. Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief. J Pain Symptom Manage 2008;35:563-7
9. Davies AN, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 2009;13:331-8
10. Mercadante S, Intravaia G, Villari P, et al. Intravenous morphine for breakthrough (episodic-) pain in an acute palliative care unit: a confirmatory study. J Pain Symptom Manage 2008;35:307-13
11. Mercadante S, Villari P, Ferrera P, et al. Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose. J Pain Symptom Manage 2004;27:352-9
12. Janssen PA. A review of the chemical features associated with strong morphine-like activity. Br J Anaesth 1962;34:260-8
13. Stanley TH. Fentanyl. J Pain Symptom Manage 2005;29:S67-71
14. Bennett D, Burton AW, Fishman S, et al. Consensus Panel Recommendations for the Assessment and Management of Breakthrough Pain. Part 1 assessment. Pharmacy and Therapeutics 2005;30:296-301
15. Streisand JB, Varvel JR, Stanski DR, et al. Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 1991;75:223-9
16. Egan TD, Sharma A, Ashburn MA, et al. Multiple dose pharmacokinetics of oral transmucosal fentanyl citrate in healthy volunteers. Anesthesiology 2000;92:665-73
17. Flynn Pharma ltd. Actiq Summary of Product Characteristics. 2010 [updated 2010; cited 2011 June 27]; Available from: http://www.medicines.org.uk/emc/ medicine/11145/SPC/Actiq/
18. Streisand JB, Busch MA, Egan TD, et al. Dose proportionality and pharma-cokinetics of oral transmucosal fentanyl citrate. Anesthesiology 1998; 88:305-9
19. Pather SI, Siebert JM, Hontz J, et al. Enhanced buccal delivery of fentanyl using the OraVescent drug delivery system. Drug Deliv Technol 2001;1:53-7
20. Durfee S, Messina J, Khankari RK. Fentanyl effervescent buccal tablets: enhanced buccal absorption. Am J Drug Deliv 2006;4:1-5
21. Darwish M, Kirby M, Robertson Jr P, et al. Dose proportionality of fentanyl buccal tablet in doses ranging from 600 to 1300 microg in healthy adult subjects: a randomized, open-label, four-period, crossover, single-centre study. Clin Drug Investig 2010;30:365-73
22. ProStrakan. Abstral Summary of Product Characteristics. 2010 [updated 2010; cited 2011 June 27]; Available from: http://www.abstral.co.uk/down-loads/ Abstral-SPC-060510.doc
23. Lennernas B, Hedner T, Holmberg M, et al. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol 2005;59:249-53
24. Insys Therapeutics Inc. Subsys Summary of Product Characteristics. 2012 [updated 2012; cited 2012 June 12]; Available from: http://www.drugs.com/subsys. html
25. Rauck R, Reynolds L, Geach J, et al. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2012;28:859-70
26. Meda Pharmaceuticals Inc. Onsolis Summary of Product Characteristics. 2010 [updated 2010; cited 2011 June 27]; Available from: http://www. drugs.com/pro/onsolis.html
27. Vasisht N, Gever LN, Tagarro I, et al. Single-dose pharmacokinetics of fentanyl buccal soluble film. Pain Med 2010;11:1017-23
28. Vasisht N, Gever LN, Tagarro I, et al. Evaluation of the single-and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers. J Clin Pharmacol 2010;50:785-91
29. Moksnes K, Fredheim OM, Klepstad P, et al. Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference? Eur J Clin Pharmacol 2008;64:497-502
30. Nycomed Ltd. Instanyl Summary of Product Characteristics. 2010 [updated 2010; cited 2011 June 27]; Available from: http://www.medicines.org.uk/EMC/ medicine/22242/SPC/Instanyl
31. Archimedes Pharma UK Ltd. PecFent Summary of Product Characteristics. 2010 [updated 2010; cited 2011 June 27]; Available from: http://www.med-icines. org.uk/emc/medicine/23962/SPC/pecfent/
32. Fisher A, Watling M, Smith A, et al. Pharmacokinetics and relative bioavail-ability of fentanyl pectin nasal spray 100-800 microg in healthy volunteers. Int J Clin Pharmacol Ther 2010;48:860-7
33. Christrup LL, Foster D, Popper LD, et al. Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. Clin Ther 2008;30:469-81
34. Darwish M, Kirby M, Robertson Jr P, et al. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J Clin Pharmacol 2007;47:343-50
35. Zeppetella G. Impact and management of breakthrough pain in cancer. Curr Opin Support Palliat Care 2009;3:1-6
36. Davies AN. The management of breakthrough cancer pain. Br J Nurs 2011;20:803-4, 6-7
37. Davies A, Finn A, Tagarro I. Intra-and interindividual variabilities in the phar-macokinetics of fentanyl buccal soluble film in healthy subjects: a cross-study analysis. Clin Drug Investig 2011;31:317-24
38. Mercadante S, Villari P, Ferrera P, et al. The use of opioids for breakthrough pain in acute palliative care unit by using doses proportional to opioid basal regimen. Clin J Pain 2010;26:306-9
39. Cephalon Ltd. Effentora Summary of Product Characteristics. 2010 [updated 2010; cited 2011 June 27]; Available from: http://www.medicines.org.uk/EMC/ medicine/21401/SPC/
40. Darwish M, Kirby M, Robertson P, et al. Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study. Clin Drug Investig 2007;27:605-11
41. Kaasa S, Moksnes K, Nolte T, et al. Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. J Opioid Manag 2010;6:17-26
42. Darwish M, Kirby M, Robertson Jr P, et al. Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers. J Clin Pharmacol 2007;47:56-63
43. Darwish M, Tempero K, Jiang JG, et al. Extent of fentanyl accumulation following multiple doses of fentanyl buccal tablet 400 microg in healthy Japanese volunteers. Arch Drug Inf 2008;1:50-5
44. Darwish M, Kirby M, Robertson Jr P, et al. Comparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmaco-kinetics. Clin Pharmacokinet 2006;45:843-50
45. Darwish M, Kirby M, Jiang JG, et al. Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400 microg in healthy subjects. Clin Drug Investig 2008;28:1-7
46. Kharasch ED, Hoffer C, Whittington D. Influence of age on the pharmacoki-netics and pharmacodynamics of oral transmucosal fentanyl citrate. Anesthesiology 2004;101:738-43
47. Kharasch ED, Whittington D, Hoffer C. Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. Anesthesiology 2004;101:729-37
48. Darwish M, Tempero K, Kirby M, et al. Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clin Pharmacokinet 2005;44:1279-86
49. Darwish M, Tempero K, Kirby M, et al. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. Clin Ther 2006;28:715-24
50. Darwish M, Kirby M, Robertson Jr P, et al. Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers. Clin Ther 2006;28:707-14
51. Lister N, Warrington S, Boyce M, et al. Pharmacokinetics, safety, and tolerability of ascending doses of sublingual fentanyl, with and without naltrexone, in Japanese subjects. J Clin Pharmacol 2011;51: 1195-204
52. Finn AL, Vasisht N, Stark JG, et al. Dose proportionality and pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a phase I, open-label, three-period, crossover study. Clin Drug Investig 2012; 32:63-71
53. Vasisht N, Gever LN, Tagarro I, et al. Formulation selection and pharmaco-kinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study. Clin Drug Investig 2009;29:647-54
54. Fisher A, Watling M, Smith A, et al. Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. Int J Clin Pharmacol Ther 2010;48:138-45